Get the Stockscreener App
1.845
12.14%
-0.255
After Hours:
1.85
0.005
+0.27%
Tscan Therapeutics Inc stock is traded at $1.845, with a volume of 339.39K.
It is down -12.14% in the last 24 hours and down -24.07% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
339.39K
Relative Volume:
0.76
Market Cap:
$113.86M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.0307
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-13.38%
1M Performance:
-24.07%
6M Performance:
-65.77%
1Y Performance:
-74.38%
1-Day Range:
$1.84
$2.12
1-Week Range:
$1.84
$2.1797
52-Week Range:
$1.84
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
880 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.845 | 113.86M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - The Manila Times
How Will TScan's Cancer Therapy Pipeline Impress Investors at Major Healthcare Conference? - StockTitan
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Inside TScan's Revolutionary TCR Cell Therapy Pipeline: CEO Conference Presentation Revealed - StockTitan
abrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting (NASDAQ:TCRX) - Seeking Alpha
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Barclays PLC Purchases 44,903 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal year - MSN
TScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks - MSN
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Acquired by Barclays PLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Geode Capital Management LLC - Defense World
State Street Corp Has $3.77 Million Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an inve - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Increased by Stifel Financial Corp - Defense World
TScan secures $30 million through warrant sale to Lynx1 By Investing.com - Investing.com Nigeria
TScan Therapeutics Refinances Existing Debt Facility with Silicon Valley Bank - Defense World
TScan Shares Jump 23% on Securities Purchase Agreement - MarketWatch
TScan Therapeutics announces ~$30M direct offering - MSN
TScan secures $30 million through warrant sale to Lynx1 - Investing.com
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - The Manila Times
TScan Therapeutics (TCRX) Secures $30M Premium-Priced Financing, Extends Cash Runway to 2027 - StockTitan
With 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backing - Yahoo Finance
Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX) - Defense World
TScan Therapeutics’ (TCRX) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics Secures $52.5M Loan from SVB - TipRanks
TScan Therapeutics Refinances Existing Convertible Debt - GlobeNewswire
TScan Therapeutics Secures Major $52.5M Financing Deal to Extend Cash Runway Through 2026 - StockTitan
XTX Topco Ltd Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
2 "Strong Buy"-Rated Biotech Stocks With 303% To 446% Upside Potential - Barchart
Tscan Therapeutics Inc (TCRX-Q) QuotePress Release - The Globe and Mail
tScan Therapeutics sees $385,768 purchase by Lynx1 Capital - Investing.com
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges - Investing.com India
TScan Therapeutics' SWOT analysis: TCR-T stock shows promise amid challenges By Investing.com - Investing.com South Africa
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):